{"id":30572,"date":"2014-09-08T08:30:43","date_gmt":"2014-09-08T12:30:43","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=30572"},"modified":"2014-09-08T08:30:43","modified_gmt":"2014-09-08T12:30:43","slug":"genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572","title":{"rendered":"Genocea Biosciences Inc (NASDAQ:GNCA) To Present Phase 1 Immunology Data For Novel Pneumoccocus Vaccine"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/08\/2014 (wallstreetpr) \u2013 Recently <strong>Genocea Biosciences Inc (NASDAQ:GNCA)<\/strong> <a href=\"http:\/\/www.nasdaq.com\/article\/genocea-presents-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-20140906-00012\" target=\"_blank\">presented<\/a> phase 1 immunology data from an investigational vaccine named GEN-004, which is designed to prevent disease that is caused by serotypes of pneumococcus.<\/p>\n<p style=\"text-align: justify;\"><strong>Insights of this presentation: <\/strong><\/p>\n<p style=\"text-align: justify;\">Genocea Biosciences Inc (NASDAQ:GNCA) made a presentation at ICAAC in which it revealed the phase 1 data from its initial study which was executed to prevent serotypes of pneumococcus disease. The data presented by the company showed that the study met immunogenicity, tolerability and safety objectives. The results included the inclination in the blood of T helper 17 cells. These are special and rare cells that provide immunity at mucosal and epithelial surfaces.<\/p>\n<p style=\"text-align: justify;\">According to experts, immunization with GEN-004 may reduce pneumococcus colonization in the nasopharynx with the help of TH17 T cell-mediated immune response. It is a precursor to infection that is caused by almost all the serotypes of pneumococcus. Total 90 volunteers were involved in the phase 1 study. All the volunteers were adults and healthy to prevent any adverse effect afterwards. The main objective of this study was to analyze the tolerability and safety of GEN-004. As per the reports, it was comprised of three main protein antigens i.e. SP2108, SP0148 and SP1912. The only condition set by researchers was to analyze the results without availability of aluminum hydroxide as an adjuvant.<\/p>\n<p style=\"text-align: justify;\">Researchers randomized all the subjects to attain 10, 30 or 100 \u00c2\u00b5g of each dose in the presence or absence of placebo or 350\u00c2\u00b5g aluminum hydroxide. All the participants were made receive three doses each for four weeks. The results of GEN-004 were analyzed with the help of an intramuscular injection.<\/p>\n<p style=\"text-align: justify;\"><strong>Results of the study: <\/strong><\/p>\n<p style=\"text-align: justify;\">At the end of the study, researchers found that GEN-004 was tolerated and safe at all doses after the administration of around 85 days. Commonly occurred side effects were pain, muscle aches, tenderness and fatigue.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/08\/2014 (wallstreetpr) \u2013 Recently Genocea Biosciences Inc (NASDAQ:GNCA) presented phase 1 immunology data from an investigational vaccine named GEN-004, which is designed to [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":30573,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[8827,8826,8828],"stock_ticker":[],"class_list":["post-30572","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-genocea-biosciences-inc","tag-genocea-biosciences-inc-nasdaqgnca","tag-nasdaqgnca","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Genocea Biosciences Inc (NASDAQ:GNCA) To Present Phase 1 Immunology Data For Novel Pneumoccocus Vaccine - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genocea Biosciences Inc (NASDAQ:GNCA) To Present Phase 1 Immunology Data For Novel Pneumoccocus Vaccine - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/08\/2014 (wallstreetpr) \u2013 Recently Genocea Biosciences Inc (NASDAQ:GNCA) presented phase 1 immunology data from an investigational vaccine named GEN-004, which is designed to [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-08T12:30:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/geno.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"240\" \/>\n\t<meta property=\"og:image:height\" content=\"160\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"Genocea Biosciences Inc (NASDAQ:GNCA) To Present Phase 1 Immunology Data For Novel Pneumoccocus Vaccine\",\"datePublished\":\"2014-09-08T12:30:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572\"},\"wordCount\":319,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/geno.jpg\",\"keywords\":[\"Genocea Biosciences Inc\",\"Genocea Biosciences Inc (NASDAQ:GNCA)\",\"NASDAQ:GNCA\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572\",\"name\":\"Genocea Biosciences Inc (NASDAQ:GNCA) To Present Phase 1 Immunology Data For Novel Pneumoccocus Vaccine - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/geno.jpg\",\"datePublished\":\"2014-09-08T12:30:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/geno.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/geno.jpg\",\"width\":240,\"height\":160},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genocea Biosciences Inc (NASDAQ:GNCA) To Present Phase 1 Immunology Data For Novel Pneumoccocus Vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genocea Biosciences Inc (NASDAQ:GNCA) To Present Phase 1 Immunology Data For Novel Pneumoccocus Vaccine - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572","og_locale":"en_US","og_type":"article","og_title":"Genocea Biosciences Inc (NASDAQ:GNCA) To Present Phase 1 Immunology Data For Novel Pneumoccocus Vaccine - Wall Street PR","og_description":"Boston, MA 09\/08\/2014 (wallstreetpr) \u2013 Recently Genocea Biosciences Inc (NASDAQ:GNCA) presented phase 1 immunology data from an investigational vaccine named GEN-004, which is designed to [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-08T12:30:43+00:00","og_image":[{"width":240,"height":160,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/geno.jpg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"Genocea Biosciences Inc (NASDAQ:GNCA) To Present Phase 1 Immunology Data For Novel Pneumoccocus Vaccine","datePublished":"2014-09-08T12:30:43+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572"},"wordCount":319,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/geno.jpg","keywords":["Genocea Biosciences Inc","Genocea Biosciences Inc (NASDAQ:GNCA)","NASDAQ:GNCA"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572","url":"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572","name":"Genocea Biosciences Inc (NASDAQ:GNCA) To Present Phase 1 Immunology Data For Novel Pneumoccocus Vaccine - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/geno.jpg","datePublished":"2014-09-08T12:30:43+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/geno.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/geno.jpg","width":240,"height":160},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/genocea-biosciences-inc-nasdaqgnca-to-present-phase-1-immunology-data-for-novel-pneumoccocus-vaccine-30572#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Genocea Biosciences Inc (NASDAQ:GNCA) To Present Phase 1 Immunology Data For Novel Pneumoccocus Vaccine"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/30572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=30572"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/30572\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/30573"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=30572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=30572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=30572"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=30572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}